TY - JOUR
T1 - Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain
AU - Undiagnosed Diseases Network
AU - Marbach, Felix
AU - Stoyanov, Georgi
AU - Erger, Florian
AU - Stratakis, Constantine A.
AU - Settas, Nikolaos
AU - London, Edra
AU - Rosenfeld, Jill A.
AU - Torti, Erin
AU - Haldeman-Englert, Chad
AU - Sklirou, Evgenia
AU - Kessler, Elena
AU - Ceulemans, Sophia
AU - Nelson, Stanley F.
AU - Martinez-Agosto, Julian A.
AU - Palmer, Christina G.S.
AU - Signer, Rebecca H.
AU - Acosta, Maria T.
AU - Adam, Margaret
AU - Adams, David R.
AU - Agrawal, Pankaj B.
AU - Alejandro, Mercedes E.
AU - Alvey, Justin
AU - Amendola, Laura
AU - Andrews, Ashley
AU - Ashley, Euan A.
AU - Azamian, Mahshid S.
AU - Bacino, Carlos A.
AU - Bademci, Guney
AU - Baker, Eva
AU - Balasubramanyam, Ashok
AU - Baldridge, Dustin
AU - Bale, Jim
AU - Bamshad, Michael
AU - Barbouth, Deborah
AU - Bayrak-Toydemir, Pinar
AU - Beck, Anita
AU - Beggs, Alan H.
AU - Behrens, Edward
AU - Bejerano, Gill
AU - Bennett, Jimmy
AU - Berg-Rood, Beverly
AU - Bernstein, Jonathan A.
AU - Berry, Gerard T.
AU - Bican, Anna
AU - Bivona, Stephanie
AU - Dasari, Surendra
AU - Lanpher, Brendan C.
AU - Lanza, Ian R.
AU - Morava, Eva
AU - Oglesbee, Devin
N1 - Funding Information:
Research reported in this paper was partially supported by the National Institutes of Health (NIH) Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under award number U01HG007703 (SFN, JAM-A, CGSP) and the UCLA California Center for Rare Diseases, within the Institute of Precision Health. Part of this work was supported by the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH through a grant to C.A.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The paper includes important contributions from On behalf of the Members of the Undiagnosed Diseases Network. The human embryonic material was provided by the Joint MRC/ Wellcome (MR/R006237/1) Human Developmental Biology Resource.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/8
Y1 - 2021/8
N2 - Purpose: We characterize the clinical and molecular phenotypes of six unrelated individuals with intellectual disability and autism spectrum disorder who carry heterozygous missense variants of the PRKAR1B gene, which encodes the R1β subunit of the cyclic AMP-dependent protein kinase A (PKA). Methods: Variants of PRKAR1B were identified by single- or trio-exome analysis. We contacted the families and physicians of the six individuals to collect phenotypic information, performed in vitro analyses of the identified PRKAR1B-variants, and investigated PRKAR1B expression during embryonic development. Results: Recent studies of large patient cohorts with neurodevelopmental disorders found significant enrichment of de novo missense variants in PRKAR1B. In our cohort, de novo origin of the PRKAR1B variants could be confirmed in five of six individuals, and four carried the same heterozygous de novo variant c.1003C>T (p.Arg335Trp; NM_001164760). Global developmental delay, autism spectrum disorder, and apraxia/dyspraxia have been reported in all six, and reduced pain sensitivity was found in three individuals carrying the c.1003C>T variant. PRKAR1B expression in the brain was demonstrated during human embryonal development. Additionally, in vitro analyses revealed altered basal PKA activity in cells transfected with variant-harboring PRKAR1B expression constructs. Conclusion: Our study provides strong evidence for a PRKAR1B-related neurodevelopmental disorder.
AB - Purpose: We characterize the clinical and molecular phenotypes of six unrelated individuals with intellectual disability and autism spectrum disorder who carry heterozygous missense variants of the PRKAR1B gene, which encodes the R1β subunit of the cyclic AMP-dependent protein kinase A (PKA). Methods: Variants of PRKAR1B were identified by single- or trio-exome analysis. We contacted the families and physicians of the six individuals to collect phenotypic information, performed in vitro analyses of the identified PRKAR1B-variants, and investigated PRKAR1B expression during embryonic development. Results: Recent studies of large patient cohorts with neurodevelopmental disorders found significant enrichment of de novo missense variants in PRKAR1B. In our cohort, de novo origin of the PRKAR1B variants could be confirmed in five of six individuals, and four carried the same heterozygous de novo variant c.1003C>T (p.Arg335Trp; NM_001164760). Global developmental delay, autism spectrum disorder, and apraxia/dyspraxia have been reported in all six, and reduced pain sensitivity was found in three individuals carrying the c.1003C>T variant. PRKAR1B expression in the brain was demonstrated during human embryonal development. Additionally, in vitro analyses revealed altered basal PKA activity in cells transfected with variant-harboring PRKAR1B expression constructs. Conclusion: Our study provides strong evidence for a PRKAR1B-related neurodevelopmental disorder.
UR - http://www.scopus.com/inward/record.url?scp=85104307618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104307618&partnerID=8YFLogxK
U2 - 10.1038/s41436-021-01152-7
DO - 10.1038/s41436-021-01152-7
M3 - Article
C2 - 33833410
AN - SCOPUS:85104307618
SN - 1098-3600
VL - 23
SP - 1465
EP - 1473
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 8
ER -